MedTech Outlook named Epi proColon test creator Epigenomics AG one of its 2019 Top 10 In-Vitro Diagnostic Award winners.
What you should know:
1. MedTech Outlook created the award to recognize companies excelling in their respective fields.
2. Epigenomics received the award for its noninvasive blood-based cancer diagnostic tests.
3. One such test, Epi proColon, is a blood-based colorectal cancer test. It is available in the U.S., Europe and China.
Epigenomics CEO Greg Hamilton said, "We believe that Epi proColon could help address the unmet medical need for new, noninvasive strategies for colorectal cancer detection."